BioMerieux (FRA:EYWN) Accounts Payable: €262 Mil (As of Dec. 2025)


FRA:EYWN BioMerieux SA FRA:EYWN
84 GF Score
Price €70.30
GF Value €111.02
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is BioMerieux Accounts Payable?

BioMerieux FRA:EYWN +0.86% 84 Accounts Payable is €262 Mil as of Dec. 2025. GuruFocus rates FRA:EYWN with a GF Score™ of 84/100 and a GF Value™ of €111.02 (Significantly Undervalued). The stock has 3 warning signs investors should review.

BioMerieux's Accounts Payable for the quarter that ended in Dec. 2025 was €262 Mil.

BioMerieux's quarterly Accounts Payable declined from Dec. 2024 (€272 Mil) to Jun. 2025 (€229 Mil) but then increased from Jun. 2025 (€229 Mil) to Dec. 2025 (€262 Mil).

BioMerieux's annual Accounts Payable increased from Dec. 2023 (€265 Mil) to Dec. 2024 (€272 Mil) but then declined from Dec. 2024 (€272 Mil) to Dec. 2025 (€262 Mil).

BioMerieux Accounts Payable Historical Data

* Premium members only.

The historical data trend for BioMerieux's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioMerieux Accounts Payable Chart

BioMerieux Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 239.50 269.40 265.10 272.40 262.10

BioMerieux Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 265.10 215.70 272.40 228.90 262.10
FRA:EYWN
84GF Score
BioMerieux SA FRA:EYWN
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioMerieux Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €262 Mil mean?
BioMerieux (FRA:EYWN) has a Accounts Payable of €262 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on BioMerieux and its competitors.
Is BioMerieux's Accounts Payable too high?
BioMerieux's current Accounts Payable is €262 Mil. Overall, BioMerieux has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMerieux's Accounts Payable compare to TMO and DHR?
BioMerieux's Accounts Payable of €262 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Medical Diagnostics & Research company?
A good Accounts Payable depends on the Medical Diagnostics & Research industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on BioMerieux and its competitors. BioMerieux's current Accounts Payable is €262 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMerieux stock overvalued right now?
Based on GuruFocus' analysis, BioMerieux (FRA:EYWN) is currently considered Significantly Undervalued. The stock's GF Value™ is €111.02, compared to a current price of €70.30 — trading 36.7% below its estimated fair value. The current Accounts Payable is €262 Mil. BioMerieux's overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For BioMerieux (FRA:EYWN), the current Accounts Payable is €262 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioMerieux (FRA:EYWN) Overvalued in 2026?

Based on GuruFocus' analysis, BioMerieux stock appears to be undervalued. The current stock price of €70.30 is trading 36.7% below its estimated GF Value™ of €111.02. GuruFocus considers BioMerieux to be Significantly Undervalued.

Key valuation signals for FRA:EYWN:

  • Accounts Payable: €262 Mil
  • GF Value™: €111.02 vs. price of €70.30 (36.7% below fair value)
  • GF Score™: 84/100 with 3 warning signs

No single metric tells the full story. See the FRA:EYWN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioMerieux Business Description

Address Marcy l’Etoile, Lyon, FRA, 69280
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.
84GF Score

Get the complete analysis for FRA:EYWN

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€70.30
Price
€111.02
GF Value